Tunstall Healthcare

Industrial Impact

UNITY | December 21, 2021

UNITY Biotechnology, Inc. a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, announced it has signed an exclusive agreement licensing its α-Klotho asset to Jocasta Neuroscience, Inc. for development and commercialization. The α-Klotho protein is a circulating factor associated with improved cognitive performance in preclinical studies. α-Klotho is hypothesized to optimize synaptic neurotransmission of N-methyl-D-aspartate...

Cell and Gene Therapy, MedTech

Nkarta, Inc. | December 06, 2022

Nkarta, Inc. a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive updated data from its Phase 1 dose escalation study of NKX019 as monotherapy to treat patients with relapsed or refractory non-Hodgkin lymphoma. Seven of ten patients treated at the higher dose levels in a three-dose regimen showed a complete response including two patients with aggressive large B cell lymphoma one patient with mantle cell lymphoma...

Cell and Gene Therapy

Verge Genomics | October 17, 2022

Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence and human data to develop new drugs, announced today that Goldman Sachs is recognizing Verge’s Chief Executive Officer and co-founder, Alice Zhang, as one of the Most Exceptional Entrepreneurs of 2022 at its Builders and Innovators Summit in Healdsburg, California. Goldman Sachs selected Zhang from leaders and entrepreneurs across multiple industries. Verge deeply integrates n...

MedTech, Industrial Impact

INOVIO Pharmaceuticals, Inc. | February 01, 2023

On January 31, 2023, INOVIO, a leading biotechnology firm focused on the development and commercialization of DNA medicines to protect and treat people from cancer, HPV-associated diseases, and infectious diseases, announced a strategic reorganization to meet operational efficiency commitments and better position the company to deliver DNA medicines to patients. Following the previously announced end of clinical development projects in late 2022, the restructuring is estimated t...